Previous 10 | Next 10 |
2023-11-13 11:23:34 ET More on Legend Biotech, Novartis, etc. Sandoz Group: Novartis Spinoff With A Double-Digit EBITDA CAGR Through 2028 New And Improved Novartis Novartis AG (NVS) Q3 2023 Earnings Call Transcript FDA approves Novartis drug Cosentyx for hidr...
2023-11-11 10:40:00 ET Summary Sandoz is a global leader in the generics and biosimilars sector, with a strong position in the off-patent medicines market. The company recently listed and plans to aggressively pursue a slice of the $208 billion (and increasing) global off-patent m...
2023-11-10 12:14:28 ET More on Celldex Celldex: Mast Cell Disease Targeting Continues To Make Advancements In Clinic Celldex Therapeutics announces pricing of public offering of common stock Celldex Therapeutics announces proposed public offering of common stock ...
2023-11-08 01:20:02 ET Summary Bausch + Lomb has made two acquisitions in a short period of time. The acquisitions are huge and are financed by debt. I think Bausch + Lomb is taking unnecessary risks. However, Bausch + Lomb remains a great company with a safe and consistent ea...
2023-11-06 17:56:31 ET Summary iShares MSCI EAFE ETF provides exposure to large and mid-sized companies across developed markets outside the U.S. and Canada. EFA has a diverse portfolio with holdings in sectors such as financials, healthcare, industrials, consumer discretionary, a...
2023-11-06 10:15:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2023-11-05 12:17:29 ET Summary The UST yield curve has steepened and this could provide an opportunity to buy US banking stocks on weakness in a no-recession scenario. Japan and Eurozone exporters can benefit from a global downturn due to easier central bank policies depreciating ...
2023-11-01 08:30:58 ET NetworkNewsWire Editorial Coverage New York, NY – November 1, 2023 – GLP-1 agonists have become incredibly popular obesity drugs, reshaping the standard of care as people increasingly turn to the new class of drugs in lieu of conventional...
2023-10-31 17:22:08 ET More on Novartis New And Improved Novartis Novartis AG (NVS) Q3 2023 Earnings Call Transcript Novartis AG (NVS) Shareholder Analyst Call (Transcript) Novartis hits main goal in Phase 3 trial for kidney disease therapy Novartis r...
2023-10-30 15:11:22 ET More on Novartis, Novartis AG, etc. New And Improved Novartis Novartis AG (NVS) Q3 2023 Earnings Call Transcript Novartis AG (NVS) Shareholder Analyst Call (Transcript) Novartis reports Q3 earnings boosted by strong sales of key drugs a...
News, Short Squeeze, Breakout and More Instantly...
2024-07-19 04:04:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-18 16:45:16 ET Image source: The Motley Fool. Novartis Ag (NYSE: NVS) Q2 2024 Earnings Call Jul 18, 2024 , 8:00 a.m. ET Operator Continue reading For further details see: Novartis Ag (NVS) Q2 2024 Earnings Call Transcript
2024-07-18 14:15:34 ET By most standards shares of drugmaker Novartis (NYSE: NVS) should be higher following this morning's release of its second-quarter results. The drugmaker's top and bottom lines were both better than expected, and up from year-earlier comparisons. And profit gu...